← All trials
NCT05011149
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2021
- Primary completion
- Apr 30, 2023
- Completion date
- Aug 31, 2023
- First posted
- Aug 18, 2021
- Last posted
- Aug 18, 2021
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dalhousie UniversityLead sponsor
- Laval UniversityCollaborator
- Dalhousie UniversityReponsible party - principal investigator
- University of TorontoCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- University of TorontoCollaborator
- University of British ColumbiaCollaborator
- University of California, IrvineCollaborator
- Dalhousie UniversityCollaborator
- Dalhousie UniversityOverall official - principal investigator
- Sharp Mary Birch Hospital for Women & Newborns, San Diego, CACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.